Index RUT
P/E -
EPS (ttm) -0.44
Insider Own 22.31%
Shs Outstand 169.87M
Perf Week -10.07%
Market Cap 758.90M
Forward P/E -
EPS next Y -0.35
Insider Trans -0.02%
Shs Float 146.67M
Perf Month 3.88%
Income -77.09M
PEG -
EPS next Q -0.09
Inst Own 51.17%
Short Float 4.13%
Perf Quarter 31.80%
Sales 10.06M
P/S 75.44
EPS this Y 12.27%
Inst Trans 4.32%
Short Ratio 5.52
Perf Half Y 57.65%
Book/sh 0.65
P/B 6.20
EPS next Y 9.33%
ROA -45.77%
Short Interest 6.06M
Perf Year 101.00%
Cash/sh 0.75
P/C 5.34
EPS next 5Y -
ROE -59.96%
52W Range 1.69 - 4.72
Perf YTD 60.80%
Dividend Est. -
P/FCF -
EPS past 5Y 18.41%
ROI -59.55%
52W High -14.92%
Beta 1.91
Dividend TTM -
Quick Ratio 6.56
Sales past 5Y 55.33%
Gross Margin 85.70%
52W Low 137.87%
ATR (14) 0.19
Dividend Ex-Date -
Current Ratio 6.56
EPS Y/Y TTM 4.48%
Oper. Margin -819.28%
RSI (14) 47.37
Volatility 4.81% 4.42%
Employees 73
Debt/Eq 0.06
Sales Y/Y TTM -57.25%
Profit Margin -766.20%
Recom 1.40
Target Price 5.00
Option/Short Yes / Yes
LT Debt/Eq 0.06
EPS Q/Q -2.33%
Payout -
Rel Volume 6.31
Prev Close 4.14
Sales Surprise -2.29%
EPS Surprise -14.58%
Sales Q/Q -62.89%
Earnings Aug 01 BMO
Avg Volume 1.10M
Price 4.02
SMA20 -3.28%
SMA50 2.94%
SMA200 32.46%
Trades
Volume 6,929,737
Change -2.90%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-02-22 Upgrade
Jefferies
Hold → Buy
$5
Feb-25-21 Initiated
Jefferies
Hold
$5
Dec-17-20 Initiated
H.C. Wainwright
Buy
$10
Jul-27-20 Resumed
JMP Securities
Mkt Outperform
$10 → $8
Jul-24-20 Downgrade
Robert W. Baird
Outperform → Neutral
May-19-20 Upgrade
Wedbush
Neutral → Outperform
Mar-06-20 Upgrade
Chardan Capital Markets
Neutral → Buy
$5
Feb-20-20 Initiated
Robert W. Baird
Outperform
$8
Feb-05-20 Upgrade
JMP Securities
Mkt Perform → Mkt Outperform
$10
Oct-07-19 Reiterated
B. Riley FBR
Buy
$7 → $3
Oct-04-19 Downgrade
Chardan Capital Markets
Buy → Neutral
Oct-16-18 Upgrade
B. Riley FBR
Neutral → Buy
$11.50 → $9
Oct-15-18 Upgrade
Wedbush
Underperform → Neutral
$5
Oct-12-18 Reiterated
Chardan Capital Markets
Buy
$12 → $6.50
Jul-06-18 Downgrade
B. Riley FBR, Inc.
Buy → Neutral
$9 → $9
Mar-19-18 Resumed
Chardan Capital Markets
Buy
$8.25
Mar-19-18 Downgrade
Wedbush
Outperform → Neutral
$9 → $6
Jan-05-18 Initiated
B. Riley FBR, Inc.
Buy
$10
Apr-04-17 Upgrade
Chardan Capital Markets
Neutral → Buy
$3 → $6
Feb-01-17 Reiterated
Wedbush
Outperform
$13 → $10
Show Previous Ratings
Sep-03-24 07:30AM
Aug-22-24 09:40AM
Aug-06-24 09:40AM
Aug-02-24 01:51AM
(Thomson Reuters StreetEvents)
Aug-01-24 08:40AM
07:41AM
Loading…
07:41AM
(Associated Press Finance)
07:30AM
Jul-18-24 07:30AM
Jun-06-24 11:15AM
11:15AM
Jun-05-24 02:30AM
May-29-24 07:30AM
May-22-24 02:00AM
May-17-24 12:03PM
10:40AM
09:00AM
Loading…
09:00AM
May-07-24 07:30AM
May-03-24 11:19AM
03:24AM
May-02-24 12:55PM
08:58AM
08:45AM
07:44AM
(Associated Press Finance)
07:30AM
07:25AM
Apr-30-24 09:40AM
Apr-18-24 07:30AM
Apr-04-24 08:30AM
Mar-08-24 07:30AM
Mar-01-24 08:17AM
11:14PM
Loading…
Feb-29-24 11:14PM
(Thomson Reuters StreetEvents)
08:40AM
07:52AM
07:30AM
Feb-15-24 07:30AM
Jan-08-24 07:30AM
Nov-09-23 04:24PM
04:01PM
09:12AM
Nov-08-23 07:30AM
01:16AM
(Thomson Reuters StreetEvents)
Nov-07-23 08:05AM
07:40AM
(Associated Press Finance)
07:30AM
07:15AM
Oct-30-23 09:32AM
Oct-24-23 07:30AM
Oct-18-23 07:30AM
Oct-11-23 08:05AM
Sep-12-23 10:56AM
(American City Business Journals) -7.73%
08:58AM
Sep-11-23 04:15PM
Sep-07-23 07:30AM
Aug-04-23 03:29PM
Aug-03-23 08:55AM
07:49AM
(Associated Press Finance)
07:30AM
Jul-23-23 10:19AM
Jul-20-23 07:30AM
Jul-12-23 07:30AM
Jul-10-23 04:01PM
Jun-23-23 09:40AM
Jun-21-23 07:30AM
02:01AM
Jun-07-23 09:40AM
02:01AM
Jun-01-23 11:29AM
May-31-23 07:30AM
May-30-23 09:26AM
May-29-23 10:08AM
May-22-23 09:40AM
May-17-23 07:38AM
May-09-23 12:00PM
07:30AM
May-04-23 11:52PM
(Thomson Reuters StreetEvents)
09:40AM
08:55AM
07:30AM
Apr-27-23 03:20AM
Apr-25-23 11:57AM
11:50AM
07:30AM
Apr-20-23 07:30AM
Apr-18-23 04:01PM
02:18PM
Apr-12-23 12:37PM
Apr-11-23 03:30PM
01:00PM
Apr-04-23 04:08PM
08:22AM
08:17AM
07:52AM
Mar-24-23 12:29PM
(American City Business Journals)
Mar-19-23 10:17AM
Mar-16-23 07:30AM
Mar-14-23 04:05PM
Mar-10-23 06:36PM
Mar-06-23 01:55AM
Mar-03-23 03:50AM
(Thomson Reuters StreetEvents)
Mar-02-23 09:25AM
Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the Hepatitis B virus, SARS-CoV-2, and other coronaviruses. The company was founded on October 6, 2005 and is headquartered in Warminster, PA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
MANCHESTER KEITH S Director Aug 14 '24 Option Exercise 0.56 54,915 30,752 54,915 Aug 16 04:07 PM MANCHESTER KEITH S Director Aug 14 '24 Sale 3.69 8,846 32,637 46,069 Aug 16 04:07 PM Sims Karen Chief Medical Officer Feb 02 '24 Sale 2.31 4,358 10,078 125,542 Feb 05 07:55 PM HASTINGS DAVID C Chief Financial Officer Feb 02 '24 Sale 2.31 9,593 22,184 181,907 Feb 05 07:54 PM Sofia Michael J. Chief Scientific Officer Feb 02 '24 Sale 2.31 9,982 23,083 1,485,121 Feb 05 07:54 PM McElhaugh Michael J. Interim President & CEO Feb 02 '24 Sale 2.31 10,164 23,504 1,504,793 Feb 05 07:54 PM
Index -
P/E 2.15
EPS (ttm) 5.57
Insider Own 40.04%
Shs Outstand 806.68M
Perf Week 0.25%
Market Cap 8.85B
Forward P/E -
EPS next Y -1.11
Insider Trans 0.00%
Shs Float 443.44M
Perf Month 1.53%
Income 4.74B
PEG -
EPS next Q -0.23
Inst Own 62.33%
Short Float 8.62%
Perf Quarter 11.97%
Sales 158.30M
P/S 55.92
EPS this Y -114.22%
Inst Trans 2.84%
Short Ratio 7.04
Perf Half Y 16.67%
Book/sh 7.35
P/B 1.63
EPS next Y -48.88%
ROA 109.72%
Short Interest 38.22M
Perf Year 15.88%
Cash/sh 7.69
P/C 1.56
EPS next 5Y -
ROE 149.26%
52W Range 8.24 - 13.24
Perf YTD 6.59%
Dividend Est. -
P/FCF -
EPS past 5Y 0.08%
ROI 81.76%
52W High -9.59%
Beta 1.25
Dividend TTM -
Quick Ratio 27.75
Sales past 5Y 493.24%
Gross Margin 82.02%
52W Low 45.18%
ATR (14) 0.38
Dividend Ex-Date -
Current Ratio 27.91
EPS Y/Y TTM 541.27%
Oper. Margin -661.14%
RSI (14) 53.33
Volatility 3.00% 3.18%
Employees 908
Debt/Eq 0.07
Sales Y/Y TTM 101.44%
Profit Margin 2991.76%
Recom 1.17
Target Price 16.94
Option/Short Yes / Yes
LT Debt/Eq 0.07
EPS Q/Q 131.72%
Payout 0.00%
Rel Volume 6.78
Prev Close 11.92
Sales Surprise 79.47%
EPS Surprise 149.32%
Sales Q/Q 154.96%
Earnings Aug 08 BMO
Avg Volume 5.43M
Price 11.97
SMA20 -0.49%
SMA50 4.74%
SMA200 9.01%
Trades
Volume 36,823,334
Change 0.42%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-15-24 Initiated
Wolfe Research
Outperform
$17
Jan-05-24 Initiated
Piper Sandler
Overweight
$20
Dec-12-23 Initiated
Deutsche Bank
Buy
$14
Oct-17-23 Initiated
Guggenheim
Buy
$17
Jun-08-23 Initiated
BofA Securities
Neutral
$10.50
Oct-27-22 Initiated
JP Morgan
Overweight
$7
May-23-22 Initiated
SVB Leerink
Outperform
$6
Apr-29-22 Initiated
Cantor Fitzgerald
Overweight
$15
Dec-15-21 Initiated
Goldman
Buy
$15
Nov-08-21 Initiated
H.C. Wainwright
Buy
$14
Oct-28-21 Initiated
Citigroup
Buy
$11
Oct-26-21 Initiated
Truist
Buy
$15
Oct-26-21 Initiated
Jefferies
Buy
$10
Oct-26-21 Initiated
Cowen
Outperform
Show Previous Ratings
Sep-18-24 07:30AM
Sep-10-24 06:30AM
06:30AM
Sep-09-24 07:00AM
Sep-04-24 06:55PM
07:00AM
Loading…
Aug-08-24 07:00AM
Jul-25-24 04:05PM
May-31-24 08:04AM
May-30-24 11:53AM
08:20AM
07:00AM
May-27-24 06:28PM
06:13PM
May-16-24 04:05PM
May-08-24 02:43AM
02:04PM
Loading…
May-07-24 02:04PM
May-01-24 10:47AM
Apr-25-24 08:00AM
Apr-12-24 11:09AM
Apr-02-24 07:00AM
Mar-27-24 01:55PM
(The Wall Street Journal) +7.54%
Mar-26-24 06:22PM
Mar-17-24 08:50AM
Mar-14-24 07:04AM
Feb-15-24 02:45AM
Feb-13-24 07:00AM
Feb-10-24 02:55AM
Jan-30-24 04:05PM
Dec-27-23 08:05PM
Dec-20-23 04:30PM
(GlobeNewswire) -7.78%
+5.82%
09:00AM
Loading…
Dec-14-23 09:00AM
Nov-28-23 07:00AM
02:38AM
Nov-27-23 08:00AM
Nov-14-23 01:00PM
Nov-13-23 07:00AM
Nov-10-23 08:00AM
Oct-30-23 05:30PM
Oct-24-23 08:00AM
(The Wall Street Journal)
Oct-23-23 03:02PM
10:31AM
09:52AM
06:55AM
(The Wall Street Journal)
03:49AM
(The Wall Street Journal)
01:00AM
Oct-13-23 08:00AM
Oct-05-23 05:01AM
Oct-03-23 07:00AM
(The Wall Street Journal)
Sep-30-23 05:00AM
Sep-26-23 06:00AM
Sep-11-23 08:00AM
Sep-09-23 10:51AM
(The Wall Street Journal)
Aug-17-23 04:05PM
Aug-14-23 07:00AM
Aug-03-23 04:05PM
Aug-02-23 04:05PM
Jul-27-23 08:00AM
Jul-26-23 10:21AM
Jul-13-23 05:50PM
(The Wall Street Journal)
Jul-11-23 08:00AM
Jun-28-23 08:57AM
07:00AM
Jun-26-23 04:05PM
Jun-22-23 07:30AM
Jun-21-23 05:00PM
May-16-23 07:00AM
Apr-04-23 07:37AM
07:37AM
Mar-28-23 08:00AM
Mar-15-23 07:45AM
Mar-14-23 04:07PM
08:00AM
Mar-07-23 08:00AM
Feb-21-23 08:32PM
Feb-13-23 04:17PM
(The Wall Street Journal)
+7.77%
07:00AM
Feb-02-23 09:14PM
Feb-01-23 04:05PM
Jan-30-23 08:00AM
Jan-04-23 06:05AM
Dec-07-22 06:30AM
Dec-01-22 08:00AM
Nov-14-22 07:00AM
Nov-10-22 09:00AM
Nov-08-22 06:15AM
Nov-07-22 04:01PM
Oct-18-22 04:00PM
Aug-30-22 07:00AM
Aug-16-22 11:44AM
Aug-15-22 07:00AM
Aug-14-22 10:53AM
Aug-03-22 07:00AM
Jul-23-22 09:00AM
Jun-30-22 09:18AM
Jun-28-22 06:27AM
06:10AM
06:00AM
Jun-15-22 04:30PM
(GlobeNewswire) +7.90%
-5.21%
May-24-22 06:00AM
May-19-22 04:30PM
Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Venker Eric President & COO Feb 09 '24 Option Exercise 3.85 96,950 373,258 629,157 Feb 09 09:00 PM Venker Eric President & COO Feb 09 '24 Sale 10.92 96,950 1,058,694 532,207 Feb 09 09:00 PM Ramaswamy Vivek 10% Owner Jan 02 '24 Sale 11.05 3,000,000 33,150,000 51,929,426 Jan 03 04:56 PM Venker Eric Chief Operating Officer Oct 03 '23 Option Exercise 3.85 606,221 2,333,951 1,201,618 Oct 04 09:30 PM Venker Eric Chief Operating Officer Oct 02 '23 Option Exercise 3.85 440,752 1,696,895 1,036,149 Oct 04 09:30 PM Venker Eric Chief Operating Officer Oct 04 '23 Option Exercise 3.85 153,027 589,154 748,424 Oct 04 09:30 PM Venker Eric Chief Operating Officer Oct 03 '23 Sale 10.25 606,221 6,213,765 595,397 Oct 04 09:30 PM Venker Eric Chief Operating Officer Oct 02 '23 Sale 10.80 440,752 4,760,122 595,397 Oct 04 09:30 PM Venker Eric Chief Operating Officer Oct 05 '23 Sale 10.11 153,027 1,547,103 595,397 Oct 04 09:30 PM Roivant Sciences Ltd. Director Oct 02 '23 Buy 38.00 1,526,316 58,000,008 79,805,331 Oct 04 05:15 PM MANCHESTER KEITH S Director Sep 28 '23 Sale 11.55 6,896,144 79,650,463 5,023,787 Oct 02 09:05 PM SVF Investments (UK) Ltd 10% Owner Sep 28 '23 Sale 12.60 10,000,000 126,000,000 73,031,667 Oct 02 09:00 PM Gold Daniel Allen Director Sep 28 '23 Sale 11.55 10,000,000 115,500,000 100,804 Oct 02 08:55 PM QVT Financial LP Director by Deputization Sep 28 '23 Sale 11.55 10,000,000 115,500,000 100,804 Oct 02 08:43 PM Venker Eric President & COO Sep 27 '23 Option Exercise 3.85 500,000 1,925,000 1,095,397 Sep 29 09:30 PM Venker Eric President & COO Sep 27 '23 Sale 13.02 500,000 6,510,000 595,397 Sep 29 09:30 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite